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Identiﬁcation of a TLR2 Inhibiting Wheat Hydrolysate
Mensiena B. G. Kiewiet,* Renske Dekkers, Martine P. van Gool, Laurien H. Ulfman,
Andre Groeneveld, Marijke M. Faas, and Paul de Vos
Scope: Wheat hydrolysates are used in medical nutrition to provide
undernourished patients a readily digestible protein source, for instance to
recover from chemotherapy-induced intestinal mucosal inﬂammation. Since
many hydrolysates of diﬀerent sources can modulate the immune system,
likely via Toll-like receptors (TLRs), it is hypothesized that also wheat
hydrolysates might interact with TLR signaling, which could be a way to
prevent intestinal inﬂammation and damage.
Methods and results: The capacity of three wheat hydrolysates to modulate
immunity by interfering with TLR signaling is determined. All wheat
hydrolysates have TLR modulating eﬀects but only one has strong TLR2
inhibiting eﬀects, attenuating both TLR2/1 and TLR2/6 signaling in a reporter
cell system. This is likely induced by direct TLR2-ectodomain binding, as
conﬁrmed by ELISA. Furthermore, this TLR2 blocking hydrolysate reduces IL-6
production in human dendritic cells. Application of reversed-phase–ultra
HPLC combined with MS reveals that the presence of peptide WQIPEQSR is
associated with the observed TLR2 inhibiting capacity.
Conclusion: The study demonstrates TLR2-inhibiting capacities of a wheat
hydrolysate. The ﬁndings provide a good start for further research to
investigate whether this hydrolysate might contribute to the management of
intestinal mucosal inﬂammation in cancer patients receiving chemotherapy.
1. Introduction
Nutritional interventions with hydrolysates are used to prevent
adverse clinical outcomes in undernourished patients.[1] About
30% of hospitalized patients are at risk for undernutrition, which
leads to prolonged hospital stay, increased readmissions, and in-
creased mortality.[2,3] This malnutrition is not always caused by
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decreased appetite, but also by malab-
sorption due to intestinal issues, such as
inﬂammation of the intestinal mucosal
membrane, also referred to as intesti-
nal mucositis.[4] This may be the conse-
quence of disease, or develop as a side ef-
fect of pharmaceutical intervention. For
example, the majority of cancer patients
treated with chemotherapeutics develop
gastrointestinal mucositis, resulting in
malnutrition.[5]
Clinical nutrition to treat undernour-
ished patients with intestinal issues con-
tains high amounts of proteins,[6] that
are hydrolyzed to facilitate uptake in the
damaged intestine.[7] Wheat hydrolysates
are of special interest for this type of nu-
tritional products, due to their relatively
high peptide-bound glutamine content,[8]
compared to, for example, cow’s milk hy-
drolysates. Glutamine supplementation
was found to decrease the length of a hos-
pital stay, complications, and mortality in
critically ill patients.[9]
Besides their nutritional value, pro-
tein hydrolysates have been recognized to
actively modulate the immune system.[10] Multiple hydrolysates
were found to induce many diﬀerent immune eﬀects, including
a range of anti-inﬂammatory eﬀects.[11–14] These eﬀects could be
induced by interaction of bioactive peptides in the hydrolysates
with Toll-like receptors (TLRs), since we previously showed im-
mune eﬀects of cow’s milk hydrolysates via TLR activation or
inhibition.[15] Some studies on wheat hydrolysates also demon-
strate similar immune eﬀects.[16] Thus, we hypothesized that
wheat hydrolysates could potentially modulate immunity via TLR
signaling.
Immunomodulating eﬀects of wheat hydrolysates may be of
special interest in treatment of mucositis induced by chemother-
apy. Mucositis is a common side eﬀects of chemotherapy.[17] Cur-
rently, there is no cure for this side eﬀect of chemotherapy but
it is known that TLR signaling is involved.[18] It starts with in-
jury of epithelial and underlying cells by the chemotherapeutic
drug, which results in the release of damage associated molec-
ular patterns (DAMPs) by dying cells. These DAMPs stimulate
TLRs on neighboring epithelial cells and immune cells, and in-
duce immune activation[19] causing mucosal damage and barrier
dysfunction.[20] Especially TLR2, TLR4, and TLR9 activation has
been found to play a role in intestinal mucositis development,
and a deﬁciency in these receptors was found to be protective
against mucositis.[21,22]
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Table 1. Overview of the molecular weight distribution of the hydrolysates studied.
Samples Source Molecular weight distribution [%]
>10 000 Da 10 000–5000 Da 5000–2000 Da 2000–1000 Da 1000–500 Da <500 Da
Wheat 1 Wheat gluten 17 15 20 14 12 22
Wheat 2 Wheat gluten 1 1 5 9 18 66
Wheat 3 Wheat gluten 1 1 4 7 13 74
Inhibition of TLR2 by food components in the lumen of the
gut has been shown to be an eﬃcacious approach to prevent
mucositis.[23] Wheat hydrolysates may inhibit TLR2 on epithelial
cells or, in case of barrier disruption, inhibit intestinal immune
cell function in a similar way. Dendritic cells are of special in-
terest in this setting. Speciﬁc subtypes are located within the ep-
ithelial layer,[24] and can therefore come into contact with dietary
molecules like hydrolysates in the lumen of the gut, but also mu-
cositis inducing DAMPs. Via TLRs, these compounds can regu-
late their maturation status and cytokine production.[25] The im-
mune status of dendritic cells is suggested to play an important
role in the regulation of the intestinal inﬂammation cascade,[26]
whichmakes them interesting targets for anti-inﬂammatory food
components like hydrolysates.
Here, we studied the possible inhibiting eﬀects of three hy-
drolysates on TLR2, TLR4, and TLR9 activation, which might
contain TLR modulating proteins and peptides. We further stud-
ied the eﬀects of the most potential hydrolysate in more detail
by investigating the inhibiting eﬀects of the TLR2/1 and TLR2/6
dimers and by studying eﬀects on dendritic cell cytokine pro-
duction. We also identiﬁed the bioactive fraction within the hy-
drolysate, and identiﬁed possible bioactive peptides from this
fraction. Our technology platform containing TLR expressing
reporter cells might lead to identiﬁcation of speciﬁc wheat hy-
drolysates that not only serve as a nutrient source, but can also
serve as bioactive food component.
2. Experimental Section
2.1. Tested Materials
Wheat hydrolysates Wheat 1 (Hyvital Wheat Glutamine PU),
Wheat 2 (Hyvital Wheat Glutamine PA), and Wheat 3 (Hyvital
Wheat Glutamine PN) were obtained from FrieslandCampina
(Amersfoort, the Netherlands). During the production, the hy-
drolysates were hydrolyzed to a ﬁnal degree of hydrolysis (DH) of
approximately 10–12%. An example of a typical molecular weight
distribution (MWD) of the peptides of Hyvital Glutamine PU ob-
tained by ﬁngerprint analysis and size exclusion chromatography
is shown in Supporting Information File S1, and the MWD of all
tested hydrolysates are summarized in Table 1. The amount of
free amino acids in the hydrolysates was less than 2% (w/w). The
amino acid proﬁle of the hydrolysates is listed in Table 2. The
protein content (TN*5.79) of Hyvital Wheat Glutamine was be-
tween 76% and 79%. The samples were tested for endotoxins by
using the Limulus amebocyte lysate assay (LAL) according to the
manufacturer’s instructions (ThermoFisher Scientiﬁc, Waltham,
Table 2. Amino acid proﬁles of the hydrolysates studied.
Amino acids [mg g–1] Hydrolysate
Wheat 1 Wheat 2 Wheat 3
Alanine 19 19 17
Arginine 27 24 22
Aspartic acid 24 22 19
Cysteine 21 17 10
Glutamic acid (including glutamine) 294 342 328
Glycine 26 28 28
Histidine 14 14 8
Isoleucine 32 28 24
Leucine 54 54 47
Lysine 12 12 9
Methionine 11 9 8
Phenylalanine 42 46 42
Proline 104 114 115
Serine 31 38 31
Threonine 19 20 15
Tryptophan 5 5 2
Tyrosine 26 24 22
Valine 31 31 26
Branch chain amino acids 117 113 96
US). Endotoxin concentrations in the samples had no signiﬁcant
activating eﬀect on the cells applied.
2.2. Dosage Information
The goal of the performed experiments was to show whether hy-
drolysates can interact with TLRs, and therefore, a concentration
was chosen that was optimal for our HEK TLR reporter cell lines.
The used concentration of 2 mg mL–1 was based on our previ-
ous experience with testing dietary molecules in HEK reporter
cell assays, and it was found that the milligram range was the
concentration at which the HEK cells responded adequately and
provided enough response to be able to measure meaningful dif-
ferences between samples.[15,27] Furthermore, other in vitro ex-
periments studying hydrolysates described in literature also used
concentrations in the milligram range.[28]
Cells were inspected visually, and no toxic eﬀects were
observed after incubation with the hydrolysates. The studied
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hydrolysates are intended to be used in clinical nutrition during
a limited time of illness. In these products, the protein concen-
tration is relatively high, since a higher protein intake (up to
1.5 g kg–1 d–1, for example, 20 g of protein taken at once) is recom-
mended in patients with intestinal inﬂammation.[29] During the
intake of this signiﬁcant amount of protein at once, it is expected
that a protein concentration of 2 mg mL–1 can be reached in the
lumen of the gut. The protein concentrations used in the in vitro
setting are therefore assumed to be physiologically relevant.
2.3. Inhibition Assay Using HEK-XBlue-hTLR2,
HEK-XBlue-hTLR4, and HEK-XBlue-hTLR29 Reporter Cells
To test whether the wheat hydrolysates are able to inhibit TLR2,
TLR4, and TLR9 activation induced by known ligands, the sam-
ples were tested on a HEK-XBlue-hTLR2, HEK-XBlue-hTLR24,
and HEK-XBlue-hTLR29 (Invivogen, Toulouse, France) reporter
cell assay. To quantify TLR activation, the cell line contains both
a TLR construct and a construct for secreted embryonic alkaline
phosphatase (SEAP), which was coupled to the nuclear factor
κB/activating protein-1 (NF-κB/AP-1) promoter. NF-κB/AP-1 is
a known downstream target of TLR receptors.[30,31]
Cell culturing and the cell assay were performed following
the manufacturer’s instructions, and as described before.[30] This
method is also described in detail in the Supporting Informa-
tion File S2. Since the most striking inhibiting eﬀect was ob-
served by 2 mg mL–1 Wheat 1 on TLR2, this eﬀect was fur-
ther investigated. The dose dependency of the overall TLR2
inhibition was tested by stimulating HEK-XBlue-hTLR2 cells
with graded concentrations of wheat hydrolysate, and HKLM.
The TLR2 receptor forms heterodimers with TLR1 and TLR6
in order to recognize a broader range of ligands[32] and stim-
ulate diﬀerent immune pathways.[33,34] In order to investigate
whether TLR2 inhibition is mediated via the TLR2/TLR1 or
TLR2/TLR6 heterodimer, the above experiment was repeated us-
ing the TLR2/TLR1 speciﬁc tri-acetylated lipopeptide P3CSK4
(25 ngmL–1)[35] and the TLR2/TLR6 speciﬁc di-acetylated lipopep-
tide FSL-1 (25 ngmL–1)[36] as activating ligands instead of HKLM.
2.4. TLR2 ELISA
HEK293T cells expressing TLR2-ectodomain-HA, which had pre-
viously been developed,[23] were ﬁrst expanded in T162 ﬂasks
with 50 µg mL–1 Blasticidin. TLR2-ectodomain-HA protein was
immunoprecipitated as described before.[23] TLR2 ELISA has
been developed in our group before and has been performed as
described.[23] In short, ELISA plates (Corning, Tewksbury, MA,
USA) were treated with 50 µL of 50 µg mL–1 poly-l-lysine for 1 h
at 37 °C.Wells werewashed oncewith 400µL ELISAbuﬀer (1mm
CaCl2 and 150mmNaCl in 0.05mTris, pH 8.2). 1mgmL–1 Wheat
1 in ELISA buﬀer was applied to the wells, and the plate was in-
cubated for 4 h at 37 °C. Wells were then washed with ELISA
buﬀer and blocked overnight with 3% milk powder (Friesland-
Campina, Amersfoort, the Netherlands) in ELISA buﬀer (100 µL
per well) at 4 °C. After washing the plate once with ELISA buﬀer,
isolated TLR2-ectodomain-HA protein was applied to the wells
at 10 µg per well and 1 µg per well and incubated for 3 h at
37 °C. As a negative control, 10 µg per well and 1 µg per well
HA peptide was also applied to wells. After incubation, the plate
was washed ﬁve times with ELISA buﬀer and incubated for 2 h
at 37 °C with 50 µL mouse-anti-HA tag antibody (1:200 in 1:2
blocking buﬀer in ELISA buﬀer; Cell signaling, Danvers, MA,
USA). After washing the plate again for ﬁve times, 50 µL goat-
anti-mouse biotin antibody was applied to the wells for 1 h at
37 °C (1:500 in 1:2 blocking buﬀer in ELISA buﬀer; Southern
Biotechnology, Birmingham, AL, USA). Then, wells were washed
ﬁve times with ELISA buﬀer, and subsequently incubated for 1 h
at 37 °C with streptavidin-HRP antibody (1:1000 in 1:2 blocking
buﬀer in ELISA buﬀer; Dako, Glostrup, Denmark). Finally, the
plate was washed seven times with ELISA buﬀer, and incubated
for 30 min at 37 °C with 100 µL TMB (Cell signaling, Danvers,
MA, USA). The reaction was stopped by adding 100 µL stop so-
lution (Cell signaling, Danvers, MA, USA). Absorbance (450 nm)
was quantiﬁed using a VersaMax microplate reader (Molecular
DevicesGmbH, Biberach an der Riss, Germany) and SoftMax Pro
Data Acquisition & Analysis Software.
2.5. Direct Stimulation of Dendritic Cells (DCs) with Wheat
Hydrolysate
To investigate the direct eﬀects of wheat hydrolysate on human
DCs, cytokine production was measured after stimulation of im-
mature DCs (MatTek Corporation, Ashland, MA, USA) with the
wheat hydrolysate for 24 h. These cells are described to express
TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, and TLR9.
Stimulations were performed by seeding 6 × 104 per well
freshly thawed DCs in each well of a 96-well plate (in 200 µL).
Cells were precultured for 24 h as described in the manufac-
turer’s instructions. Then, cells were exposed to 2 mg mL–1
hydrolysate and 107 cells mL–1 HKLM, after which cells were
incubated for 24 h (37 °C, 5% CO2). HKLM alone was used as
a positive control, medium as a negative control. To assess the
role of TLR2 inhibition in the eﬀects observed, instead of the
hydrolysate, cells were treated with 5 µg mL–1 TLR2 blocking
antibody (PAb-hTLR2, Invivogen, Toulouse, France) for 30 min,
after which HKLM was added. Supernatant was collected and
stored at –80 °C for cytokine measurements.
2.6. Assessment of Cytokine Expression
The levels of IL-1β, IL-1RA, IL-10, IL-12, IL-6, IL-8,MCP-1/CCL2,
MIP-1α/CCL3, RANTES/CCL5, TNF-α, and TSLP in the DC
supernatant were measured using a custom-made ProcartaPlex
multiplex immunoassay (Aﬀymetrix, CA, USA). The immunoas-
say was performed according to the manufacturer’s protocol.
Brieﬂy, cytokine standards were resuspended, and serial dilu-
tions were prepared. Antibody magnetic bead mix was added
to the plate. After washing, standards and samples were added
(50 µL per well), the plate was sealed, and incubated while
shaking (30 min at room temperature (RT), overnight at 4 ̊C,
and again 30 min at RT). After washing the plate twice, detec-
tion antibodies were added (25 µL per well) and the plate was
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incubated for 30 min at RT on a plate shaker. After incuba-
tion, the plate was washed twice and 50 µL per well streptavidin-
phycoerythrin was added. Again, the plate was incubated at RT
for 30minwhile shaking. Then, the plate was washed, and 120 µL
per well of reading buﬀer was added. After shaking the plate
for 5 min at RT ﬂuorescence was measured using a Luminex
100 System. The data obtained were analyzed using StarStation
software.
2.7. Fractionation of the Hydrolysate
The hydrolysate was fractionated based on size using an Amicon
stirred cell (Merck, Nottingham, UK) with a capacity of 50 mL. In
this way, four fractions were obtained, containing peptides and
proteins >3 kDa, peptides between 3 and 1 kDa, peptides be-
tween 1 and 0.5 kDa, and peptides <0.5 kDa. A detailed descrip-
tion of the procedure can be found in Supporting Information
ﬁle S2.
The protein concentration in the pooled fractions was mea-
sured using a Pierce BCAprotein assay, followingmanufacturer’s
instructions (Thermoscientiﬁc, Pittsburgh, USA). Fractions with
a concentration less than 20 mg mL–1 were concentrated using a
SpeedVac centrifugal evaporator (ThermoScientiﬁc, Pittsburgh,
USA) for 4 h. The ﬁltered sterile water was concentrated in the
samemanner. The protein concentration of the concentrated pro-
tein fractions were measured again, and were now 20 mg mL–1
or higher. Fractions were stored at –20 °C before testing at a con-
centration of 2 mg mL–1 in the HEK-XBlue-hTLR2 cell lines as
described above.
2.8. Peptide Analysis on RP-Ultra HPLC Coupled to MS
In order to investigate which individual peptides could be respon-
sible for TLR modulating eﬀects, the peptide composition of the
speciﬁc hydrolysate was fractionated and analyzed with RP-ultra
HPLC (RP-UHPLC) coupled to MS. Technical details and a de-
scription of the procedure can be found in Supporting Informa-
tion File S2.
The mass tolerance for the accepted annotation was 10 ppm
between the theoretical mass and the measured mass, which is
generally accepted for this type of equipment and method.[37–39]
Furthermore, each of the peptide identiﬁcations are conﬁrmed
by the presence of at least one of their b/y fragments. A generic
method was used in which non-speciﬁc enzyme speciﬁcity was
selected. A list with intact wheat storage proteins used in the anal-
ysis is included as Supporting Information File S3. The peptides
were annotated by MS and conﬁrmed by MS/MS through the
presence of b and y fragment ions with an assigned intensity of
at least 50%.
Further analysis was performed by comparing the peptide
compositions of the fractions. This was done by investigating
which peptides were exclusively present in a fraction with TLR
modulating eﬀects. When peptides were present in all fractions,
it was determined whether the relative abundance (response) was
higher in the speciﬁc TLR modulating fraction compared to frac-
tions with lesser eﬀects.
2.9. Statistical Analysis
Statistical analysis was performed using Graphpad Prism. Nor-
mal distribution of the data was tested using the Kolmogorov–
Smirnov test. When data were normally distributed, values were
expressed as mean ± standard deviation (SD). Then, a t-test or
one-way ANOVA followed by t-tests was used to identify signiﬁ-
cant diﬀerences. When data were not normally distributed, val-
ues were expressed asmedian with range. Signiﬁcant diﬀerences
were in that case assessed using a Kruskal–Wallis test followed by
a Dunn’s post test. A p-value of <0.05 was considered to indicate
a statistical signiﬁcant diﬀerence.
3. Results
3.1. Characteristics of the Wheat Hydrolysates
Three diﬀerent wheat hydrolysates with diﬀerent peptide compo-
sitions were investigated (Table 1). Wheat 1 diﬀered most from
the other wheat hydrolysates as it was found that Wheat 1 con-
tained more proteins bigger than 10 kDa compared to the other
wheat hydrolysates.
3.2. Hydrolysate Wheat 1 Strongly Inhibits HKLM Induced TLR2
Activation in a dose Dependent Manner
In order to test the TLR inhibiting capacity of the wheat hy-
drolysates, HEK-XBlue-hTLR2, HEK-XBlue-hTLR4, and HEK-
XBlue-hTLR9 reporter cells were stimulated with 2 mg mL–1 hy-
drolysate and the corresponding ligands to induce TLR activation.
Wheat hydrolysates showed TLR inhibiting capacities after
TLR stimulation with a known ligand (Figure 1). Wheat 1 had the
most pronounced eﬀects. Besides a small, but statistically signif-
icant inhibition of TLR4 and TLR9 (both p < 0.05), it showed a
strong TLR2 inhibiting eﬀect (p < 0.05). Wheat 2 only inhibited
TLR4 (p < 0.05), while Wheat 3 inhibited TLR4 and TLR9 (both
p < 0.05).
Since the strongest inhibiting eﬀect was induced by Wheat
1 on TLR2, in further experiments, we only used Wheat 1 and
studied its eﬀect on TLR2 in more detail. To study the dose re-
sponse eﬀect of Wheat 1 on TLR2 inhibition, HEK-XBlue-hTLR2
cells were incubated with graded concentrations of Wheat 1 and
HKLM (107 cells per mL) (Figure 2). TLR inhibition was found
to be decreased in a dose dependent fashion. A concentration
of 1 mg mL–1 was the minimal hydrolysate concentration that
was still able to induce a signiﬁcantly decreased TLR2 activation
(p < 0.05).
3.3. Wheat 1 Inhibits TLR2 by Direct Binding to TLR2-Ectodomain
In order to determine whether the observed inhibiting eﬀect of
Wheat 1 on TLR2 signaling is due to direct binding of the hy-
drolysate to the TLR2-ectodomain, an ELISA was developed in
which binding of isolated TLR2 protein to immobilized Wheat 1
could be demonstrated. As shown in Figure 3, protein binding
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Figure 1. NF-κB /AP-1 activation in HEK-XBlue-hTLR2, HEK-XBlue-hTLR4, and HEK-XBlue-hTLR9 cells after simultaneous stimulation with its relevant
ligand and 2 mg mL–1 of the wheat hydrolysates. Wheat hydrolysates were able to inhibit TLR activation. Hydrolysate Wheat 1 inhibited activation of
TLR2, TLR4, and TLR9, with a strong inhibition of TLR2. Wheat 2 inhibited TLR4, while Wheat 3 inhibited TLR4 and TLR9. Data are expressed as median
with range (n= 5). Signiﬁcant diﬀerences were determined by using the Kruskal–Wallis test followed by the Dunn’s test. Signiﬁcant diﬀerences compared
to the negative control were indicated by *p < 0.05, **p < 0.01, ***p < 0.001), or by ****p < 0.0001, signiﬁcant diﬀerences compared to the positive
control were indicated by #p < 0.05, ##p < 0.01, ###p < 0.001, or by ####p < 0.0001.
Figure 2. NF-κB /AP-1 activation in HEK-XBlue-hTLR2 cells after simulta-
neous stimulation with 107 cells per mLHKLM and graded concentrations
ofWheat 1.Wheat 1 showed TLR2 inhibition in a dose dependent way. Data
are expressed as median with range (n = 5). Signiﬁcant diﬀerences were
determined by using the Kruskal–Wallis test followed by the Dunn’s test.
Signiﬁcant diﬀerences compared to the negative control were indicated
by *p < 0.05), **p < 0.01, ***p < 0.001, or by ****p < 0.0001, signiﬁcant
diﬀerences compared to the positive control were indicated by #p < 0.05,
##p < 0.01, ###p < 0.001, or by ####p < 0.0001.
of TLR2-ectodomain to Wheat 1 coated wells was signiﬁcantly
higher (p < 0.05) compared to the HA negative control when
wells were loaded with the TLR2 protein. This indicates that di-
rect binding of wheat peptides to TLR2-ectodomain occurs.
3.4. Wheat 1 was Able to Inhibit Both TLR2/TLR1 and TLR2/TLR6
Signaling
TLR2 is able to form a heterodimer with either TLR1 or TLR6,
which leads to diﬀerent downstream immune responses.[33,34] In
Figure 3. Wheat 1 showed a TLR2-ectodomain binding eﬀect. ELISA was
performed to demonstrate TLR2-ectodomain binding properties of Wheat
1. ELISA wells were loaded with either 10 µg TLR2-ectodomain protein. HA
peptide was used as a negative control. Data are expressed as mean with
SD (n = 5). Statistical signiﬁcant diﬀerences compared to the negative
control were determined by using a t-test and indicated by *.
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Figure 4. NF-κB /AP-1 activation in HEK-XBlue-hTLR2 cells after simultaneous stimulation with either the TLR2/1 ligand P3CSK4 or the TLR2/6 ligand
FSL-1 and graded concentrations of Wheat 1. Wheat 1 showed TLR2 inhibition in a dose dependent way, both in 25 ngmL–1 P3CSK4 and 25 ngmL–1 FSL-
1 stimulated cells. Data are expressed as median with range (n = 5). Signiﬁcant diﬀerences were determined by using the Kruskal–Wallis test followed
by the Dunn’s test. Signiﬁcant diﬀerences compared to the negative control were indicated by *p < 0.05, **p < 0.01, ***p < 0.001, or by ****p < 0.0001,
signiﬁcant diﬀerences compared to the positive control were indicated by #p < 0.05, ##p < 0.01, ###p < 0.001, or by ####p < 0.0001.
Figure 5. Cytokine production in DCs stimulated with Wheat 1, HKLM, or a combination. Wheat 1 (2 mg mL–1) increased IL-12 and IL-10 production
in DCs, either alone or in combination with HKLM. Wheat 1 was able to inhibit HKLM induced IL-6 production. Preincubation of DCs with a TLR2
antibody showed the same eﬀect. Data are expressed as mean with SD (n = 5). Statistical signiﬁcant diﬀerences compared to the negative control were
determined by using t-tests and indicated by *.
order to determine the heterodimer speciﬁcity of the TLR2 in-
hibiting eﬀect of Wheat 1, HEK-XBlue-hTLR2 reporter cells were
incubated with diﬀerent concentrations of Wheat 1 together with
either the TLR2/TLR1 ligand P3CSK4[35] or the TLR2/TLR6 lig-
and FSL-1.[36]
As shown in Figure 4,Wheat 1was able to inhibit both P3CSK4
and FSL-1 induced TLR2 activation. Both for P3CSK4 and FSL-
1 stimulated cells, 1 mg mL–1 was the lowest hydrolysate con-
centration that was still able to induce a statistically signiﬁcant
decreased TLR2 activation compared to ligand stimulated cells
(p < 0.05).
3.5. Wheat 1 Decreased HKLM Induced IL-6 Production in DCs
Next, we investigated the eﬀects ofWheat 1 onHKLM stimulated
human DCs. DCs are important in orchestrating intestinal im-
mune responses.[40,41] Figure 5 shows the eﬀects of 2 mg mL–1
Wheat 1 on the production of the regulatory cytokine IL-10,
the proinﬂammatory cytokine IL-12 and the pleiotropic cytokine
IL-6 of HKLM stimulated DCs, which are associated with DC
activation.[42] Eﬀects on other cytokines measured are shown in
Supporting Information File S4.
The production of IL-12 was signiﬁcantly increased after DC
stimulation for 24 h with either Wheat 1 alone or HKLM alone
compared to the negative control (both p< 0.05).WhenDCswere
treated with a combination of TLR2 activating HKLM andWheat
1, IL-12 production was also signiﬁcantly increased compared to
unstimulated cells (p < 0.05), and this eﬀect was even signiﬁ-
cantly higher compared to DCs treated with HKLM alone. The
TLR2 blocking antibody had no eﬀect on the IL-12 production of
HKLM stimulated cells.
For IL-10, a similar eﬀect was observed. Stimulation of DCs
with Wheat 1 alone increased IL-10 production signiﬁcantly
(p < 0.05), while HKLM stimulation had no signiﬁcant eﬀect
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Figure 6. NF-κB /AP-1 activation in HEK-XBlue-hTLR2 cells after simulta-
neous stimulation with 107 cells per mL HKLM and diﬀerent size based
fractions of Wheat 1. Only the two smallest fractions, 1–0.5 kDa and
<0.5 kDa, showed TLR2 inhibition in HKLM stimulated cells. Data were
expressed asmedian with range (n= 5). Signiﬁcant diﬀerences were deter-
mined by using the Kruskal–Wallis test followed by the Dunn’s test. Sig-
niﬁcant diﬀerences compared to the negative control were indicated by
*p < 0.05, **p < 0.01), ***p < 0.001, or by ****p < 0.0001, signiﬁcant dif-
ferences compared to the positive control were indicated by #p < 0.05,
##p < 0.01, ###p < 0.001, or by ####p < 0.0001.
on IL-10 production by DCs. DCs treated with a combination
of Wheat 1 and HKLM did result in an increased IL-10 produc-
tion, which was signiﬁcantly diﬀerent from both the unstimu-
lated cells and HKLM treated cells (both p < 0.05). Again, the
TLR2 blocking antibody did not aﬀect HKLM stimulated DC IL-
10 production.
For IL-6 another eﬀect was observed. StimulationwithWheat 1
alone did not change IL-6 production of DCs, while HKLM stim-
ulation signiﬁcantly increased IL-6 production compared to the
IL-6 production of untreated cells (p < 0.05). Interestingly DCs
were treated with a combination of HKLM andWheat 1, IL-6 pro-
duction was signiﬁcantly decreased compared to DCs stimulated
with HKLM alone (p < 0.05). This eﬀect could be induced via
TLR2, since the IL-6 production in DCs treated with HKLM af-
ter preincubation with the TLR2 blocking antibody was similar
to DCs treated with HKLM and Wheat 1.
3.6. The Peptide Fraction Containing Peptides Smaller than
0.5 kDa has the Strongest TLR2 Inhibiting Eﬀects
To investigate which peptide(s) in Wheat 1 are responsible for
the TLR inhibiting eﬀects, size based fractions were produced
(>3 kDa, 3–1 kDa, 1–0.5 kDa, and<0.5 kDa), and tested at a con-
centration of 2 mg mL–1 for TLR2 inhibiting eﬀects in HKLM
stimulated HEK-XBlue-hTLR2 reporter cells.
As shown in Figure 6, it was found that only the fractions
1–0.5 kDa and <0.5 kDa showed a signiﬁcantly reduced TLR2
activation compared to cells treated with HKLM alone (both
p < 0.05). The fraction containing the peptides smaller than
0.5 kDa showed the strongest TLR2 inhibiting eﬀect.
3.7. Peptides with a Potential TLR2 Inhibiting Eﬀect were
Identiﬁed in the Fraction <0.5 kDa
To identify the speciﬁc peptides responsible for the TLR2 inhibi-
tion in the fractions 1–0.5 kDa and <0.5 kDa, RP-UHPLC cou-
pled to MS was applied. The analysis also included the fraction
3–1 kDa, since this fraction contained no inhibiting eﬀect. In the
fraction 3–1 kDa 1300 peptides conﬁrmed byminimal 1 ﬁrst gen-
eration primary ion in the MS/MS signal were identiﬁed. In the
fraction 1–0.5 kDa, 930 peptides were identiﬁed, and in the frac-
tion <0.5 kDa, 861 peptides were identiﬁed (see Supporting In-
formation File S5 for complete lists).
Diﬀerences in peptide composition can already be observed
between fractions, by comparing UV absorbance proﬁles at 214
nm andmass spectrum (Supporting Information File S6 and S7).
To identify which peptides were uniquely present in TLR2 in-
hibiting fractions (<0.5 kDa and 1–0.5 kDa), the diﬀerent pep-
tides in the three fractions were compared, and only those with
an assigned intensity of 50% or higher were selected. The pep-
tide annotation was conﬁrmed for all peptides by identiﬁca-
tion of b and y fragments by MS/MS. The peptides IFWGIPA
and IAPVGIF were present in all fractions, and did not diﬀer
in relative abundance (response). The peptides MHILLP, TTI-
APFGIFGTN, ILQQQL, and VCSVSQIIMRQ were unique for
the <0.5 kDa fraction and absent in both the 1–0.5 kDa and
3–1 kDa fractions. Interestingly, the peptide WQIPEQSR (four
matched ﬁrst gen primary ions found) was present in both TLR2
inhibiting fractions, but not in the 3–1 kDa fraction without TLR2
inhibiting eﬀects (Table 3). The relative abundance (response) of
the peptide WQIPEQSR was similar in both fractions.
4. Discussion
Wheat hydrolysates are used for medical nutrition to provide un-
dernourished patients a readily digestible protein source, for ex-
ample, to recover from chemotherapy induced damage to the in-
testine. Another potential beneﬁcial eﬀect of hydrolysates ismod-
ulation of the immune system to inhibit chemotherapy-induced
intestinal damage and inﬂammation. There is evidence that Toll-
like receptors (TLRs) are involved in the induction ofmucositis[21]
and some hydrolysates have been found to be capable of TLR
modulation.[15] Therefore, we studied TLR inhibiting eﬀects of
three wheat hydrolysates used in medical nutrition.
The inhibiting capacities of the three wheat hydrolysates were
ﬁrst studied for TLR2, TLR4, and TLR9, which are all associated
with mucositis development.[21,22] They all had TLR inhibitory
eﬀects but to a varying extent and the eﬀect was highly hy-
drolysate dependent. Wheat 1 showed a strong TLR2 inhibiting
eﬀect, which was not observed for the other hydrolysates. As
shown in Figure 3, the inhibition of TLR2 activation by Wheat
1 was most likely due to direct binding of Wheat 1 to the TLR2-
ectodomain, and therewith blocking of TLR2 activation by poten-
tial proinﬂammatory DAMPs or other ligands. TLR2 has been
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Table 3. List of possible TLR2-inhibiting peptides.
Peptide Observed mass (Dalton) [M + H] Source protein Present in fraction
3–1 kDa 1–0.5 kDa <0.5 kDa
MHILLP 723 ɣ-gliadin No No Yes
TTIAPFGIFGTN 1238 α/β gliadin No No Yes
ILQQQL 742 α/β -gliadin, α-gliadin No No Yes
VCSVSQIIMRQ 1263 Avidin like A2,A3, A7 No No Yes
WQIPEQSR 1043 α/β gliadin No Yes Yes
shown before to be able to bind to proteins and (synthetic)
peptides.[43–45] The TLR2 ligand binding site has a large binding
surface with many insertions and β-sheets to which many pro-
teins can bind.[46] TLR2 is the most studied TLR in relation with
mucositis.[21,47,48] Its blockade can prevent doxorubicin-induced
mucositis.[21] Doxorubicin is one of the most potent and com-
monly applied chemotherapeutic drugs,[49] but its application is
sometimes limited by its toxicity.[50] Our data suggest that wheat
hydrolysates might be instrumental in doxorubicin treated pa-
tients by increasing its therapeutic potential due to its TLR2 in-
hibiting eﬀects. Since TLR2 regulation of the intestinal damage
was found to be chemotherapeutic drugs speciﬁc,[23] the eﬀects
of wheat hydrolysates might diﬀer between chemotherapies.
TLR2 has the unique capacity to form dimers with TLR1
or TLR6.[32] Depending on the dimer formed, more pro- or
anti-inﬂammatory responses are induced.[33,34] To better under-
stand the eﬀects of TLR2 inhibition by Wheat 1, we investigated
whether the inhibiting eﬀect was speciﬁc for TLR2/1 or TLR2/6
or a combination thereof. It was found that Wheat 1 inhibited
both TLR2/1 as well as TLR2/6 signaling (Figure 4), indicating
that Wheat 1 may block the TLR2 ligand binding site itself, in
such a way that it does not interfere with the TLR2/1 and TLR2/6
dimerization.
Stimulating DCs with Wheat 1, HKLM or a combination
had distinct eﬀects on the production of the cytokines IL-12,
IL-10, and IL-6 (Figure 5). TLR2 activation by HKLM had a pro-
nounced eﬀect on IL-6 production, which is known to be merely
TLR2 dependent.[51,52] Although IL-6 is a pleiotropic cytokine, it
is known to enhance pro-inﬂammatory events during intestinal
injury. In mucositis, IL-6, together with TNF-α and IL-1β, was
found to be signiﬁcantly increased both in blood and intestinal
tissue in animal models and patients.[53–55] Especially IL-6 levels
correlate with the severity of the inﬂammation,[56] and reduction
of IL-6 attenuates intestinal inﬂammation.[57] Here, we found that
Wheat 1 was able to inhibit the HKLM induced IL-6 production
in DCs. Therefore, administration of wheat hydrolysate might be
a new way to provide nutrients and simultaneously inhibit IL-6,
although more research is needed to conﬁrm this. IL-10 and
IL-12, nor any of the other cytokines measured, were inhibited
by Wheat 1, which conﬁrms the TLR2 speciﬁcity of the inhibit-
ing eﬀect of Wheat 1, as regulation of these cytokines depends
more on other TLR types such as TLR4.[58,59]
It is likely that only speciﬁc protein sequences in the wheat hy-
drolysate are responsible for the TLR2 binding eﬀect. Therefore,
we designed a strategy to identify the unique peptide sequences
in Wheat 1 that might be responsible for the TLR2 inhibiting ef-
fects. We obtained size based fractions of the hydrolysate and de-
tected most of the TLR2 inhibitory eﬀects in the smallest fraction
(<0.5 kDa). Four possible TLR2 inhibiting peptides in this frac-
tion were identiﬁed by analyzing the fractions using RP-UHPLC
coupled to MS and comparing their peptide composition. Since
only the peptideWQIPEQSRwas present in both fractions show-
ing TLR inhibition and since it was absent in the fraction without
TLR2 eﬀects, we propose that this peptide is most likely essential
for TLR2 inhibition. However, since none of the tested fractions
was able to recapitulate the TLR2 inhibiting eﬀect of the complete
hydrolysate, further studies should be performed to investigate
possible synergic eﬀects with other peptides. Modulation of TLR
signaling by small molecules, which do not resemble PAMPs, is
of recent interest.[45,60] Molecules have for example been found to
bind the ligand site,[61] but also intracellular regions,[62] or inter-
fere with dimerization and the downstream pathway.[63] It might
be argued that the activity of this peptide might disappear during
gastrointestinal transition due to proteolytic digestion but it is
known that WQIPEQSR will stay intact for a signiﬁcant amount
of time in the intestine, and will therefore be able to induce im-
mune eﬀect in the intestine. WQIPEQSR is a gliadin derived
peptide and very stable even after treatment with pancreatic pro-
teases, as well as after treatment with brush border proteolytic
enzymes.[64,65]
In this study, we identiﬁed a wheat hydrolysate with a strong
TLR2 inhibitory eﬀect due to binding of the TLR2-ectodomain,
which resulted in HKLM induced IL-6 inhibition in DCs. Since
TLR2 and IL-6 are recognized to be crucial in the development
of intestinal mucositis, future research should focus on testing
whether wheat hydrolysates can be applied in clinical nutrition
to attenuate mucositis. Overall, our ﬁndings provide a good start
for further research to investigate whether this hydrolysatemight
contribute to the management of mucositis in cancer patients
receiving chemotherapy.
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